GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Enhabit Inc (NYSE:EHAB) » Definitions » Sloan Ratio %

Enhabit (Enhabit) Sloan Ratio % : -8.02% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Enhabit Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Enhabit's Sloan Ratio for the quarter that ended in Mar. 2024 was -8.02%.

As of Mar. 2024, Enhabit has a Sloan Ratio of -8.02%, indicating the company is in the safe zone and there is no funny business with accruals.


Enhabit Sloan Ratio % Historical Data

The historical data trend for Enhabit's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enhabit Sloan Ratio % Chart

Enhabit Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
- 3.28 6.22 -5.12 -8.62

Enhabit Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.76 -11.20 -12.05 -8.62 -8.02

Competitive Comparison of Enhabit's Sloan Ratio %

For the Medical Care Facilities subindustry, Enhabit's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enhabit's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Enhabit's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Enhabit's Sloan Ratio % falls into.



Enhabit Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Enhabit's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-80.5-48.4
--5.3)/1433.6
=-8.62%

Enhabit's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-83-36.1
--3.2)/1445.2
=-8.02%

Enhabit's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -74.4 (Jun. 2023 ) + -2.4 (Sep. 2023 ) + -6.4 (Dec. 2023 ) + 0.2 (Mar. 2024 ) = $-83 Mil.
Enhabit's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was 9.6 (Jun. 2023 ) + 6.3 (Sep. 2023 ) + 2.9 (Dec. 2023 ) + 17.3 (Mar. 2024 ) = $36 Mil.
Enhabit's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.8 (Jun. 2023 ) + -1.8 (Sep. 2023 ) + 0.5 (Dec. 2023 ) + -1.1 (Mar. 2024 ) = $-3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enhabit  (NYSE:EHAB) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Enhabit has a Sloan Ratio of -8.02%, indicating the company is in the safe zone and there is no funny business with accruals.


Enhabit Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Enhabit's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enhabit (Enhabit) Business Description

Traded in Other Exchanges
Address
6688 N. Central Expressway, Suite 1300, Dallas, TX, USA, 75206
Enhabit Inc provides home health and hospice services in the United States. It offers care where patients prefer it: in their homes. It operates business in two segments: home health and hospice. Its home health agencies provide a comprehensive range of Medicare-certified skilled home health services, including skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services.
Executives
Jeffrey Bolton director 1016 CIVIC CENTER DRIVE NW, ROCHESTER MN 55901
Shaw L Edward Jr director AETNA INC, 151 FARMINGTON AVE RC4B, HARTFORD CT 06156
Stuart M Mcguigan director 74 AGAMENTICUS AVENUE, CAPE NEDDICK ME 03902
Barry P. Schochet director 100 EAST RIVERCENTER BLVD, 16TH FLOOR, COVINGTON KY 41011
Dylan C Black officer: General Counsel and Secretary 6688 CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Langham Ronald Leroy Jr officer: EVP Clinical Excel. & Strategy 6688 CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Higdon Leo I Jr director 1700 LINCOLN STREET, 28TH FLOOR, DENVER CO 80203
Gregory S Rush director TEKELEC, 26580 W. AGOURA RD., CALABASAS CA 91302
Tina L. Brown-stevenson director 6688 N. CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Erin Hoeflinger director 511 FALLVIEW COURT, SPRINGBORO OH 45066
Tanya Renee Marion officer: Chief Human Resources Officer 6688 NORTH CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Charles M Elson director 1401 61STG STREET S, STETSON UNIV COLLEGE OF LAW, ST PETERSBURG FL 33707
Barbara Ann Jacobsmeyer director, officer: President and CEO 2122 ACTON PARK WAY, BIRMINGHAM AL 35243
Yvonne M Curl director C/O ENHABIT, INC., 6688 N. CENTRAL EXPRESSWAY, SUITE 1300, DALLAS TX 75206
Maupin John E Jr D D S director 103 POWELL COURT SUITE 200, BRENTWOOD TN 37027